Indian pharma industry showed impressive growth in April 2025, by price led expansion: Report

New Delhi [India], May 10 (ANI): The
Indian
The pharmaceutical market maintained its positive trend in April 2025, showing a robust increase of 7.8 percent compared to the previous year.
growth
With aggregate sales amounting to Rs 19,711 crore, as stated in a Pharmatrack report.

The monthly performance witnessed an additional Rs 1,424 crore in incremental sales, highlighting the sector’s ongoing strength and demand, according to the report.

Based on the report, the sales sürecin
صندBitFields
growth
was mainly fueled by cost-driven factors
expansion
, succeeded by the effect of introducing new products (NPI).

On a Moving Annual Total (MAT) basis, the report also mentioned that the
industry
rose to Rs 2,27,361 Crore, indicating a yearly increase
growth
at an 8.3 percent rate and a robust 10.3 percent Compound Annual
growth
measure (CAGR), showcasing the sector’s resilience and long-term stability
growth
potential.

The drive behind this growth on April 25 was fueled by therapeutic areas such as Cardiovascular, Neurological/Central Nervous System, Hematology, Anticancer drugs, Ophthalmology/Otolaryngology, and Urology. This underscores the key role that specialized and long-term treatments play in boosting the market.
expansion
.

This performance highlights the
industry
Implementing effective pricing strategies to handle cost pressures and maintain revenue growth.
growth
, despite the total volume
growth
remained modest at 0.4 per cent, added the report.

According to the findings of the report, within various therapeutic fields, Cardiac and Anti-Infective treatments saw significant increases in volumes during April.

The report highlights that the cardiac therapy segment shows a strong trend, propelled by sustained demand in chronic disease management, particularly for Anti-Hypertensives, Lipid Lowering agents and Heart Failure therapies.

In the meantime, Anti-Infective products saw an increase in volumes due to demands from acute care settings, probably affected by seasonal illnesses and localized disease outbreaks.

Moreover, the report indicates that from a pricing perspective, respiratory therapy saw a 6.6% price hike, which was swiftly followed by cardiac and gastrointestinal treatments, highlighting the pricing trends within these highly sought-after sectors.

Stomatological products stood out in terms of new product performance, with a growth of 7.7 percent.
growth
, with an emphasis on launches in niche care sectors where competition remains comparatively low and demand is growing, the report further noted.(ANI)